There is evidence that PD-L1 is found in a higher percentage in NSCLC and it is expressed in the majority of tumor-infiltrating lymphocytes, which has been the reason for to introduce PD-L1 or PD-1 inhibitors into the treatment of NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.